

PROVEN OUTCOMES WITH BIS™ MONITORING

Reducing risk for your patients. We understand the challenges.

BIS™ monitoring helps you tailor anesthetic dosing more precisely. Maintaining BIS™ monitoring values in the range of 40 to 60 by adjusting anesthetic levels and administration may have benefits including:



Patient-specific drug titration

Studies show a reduction in anesthetic drug use for patients monitored with BIS™ technology, specifically:

- BIS™ monitoring enabled a 50% reduction in propofol administration during hypothermic cardiopulmonary bypass.¹
- For asleep-awake craniotomy surgical procedures, where titratable anesthesia is preferred to facilitate more predictable intraoperative wake-up, BIS™ monitoring can provide further information to guide drug administration and predict responsiveness.²

Improved emergence, recovery and discharge

Optimal anesthetic administration minimizes side effects and postoperative complications. Studies show that patients whose anesthetic dosing was guided by BIS™ monitoring experienced:

- Faster extubation^{3,4}
- Faster emergence³
- Better orientation at the Post-Anesthesia Care Unit (PACU)³
- Faster discharge^{3,4}

Lowered incidence of intraoperative awareness

With TIVA procedures, the incidence of awareness can be 5 to 10 times greater than with inhaled anesthetics as a result of the short-acting nature of some intravenous anesthetics used.⁵

When using BIS™ monitoring, the incidence of awareness is approximately 80% lower compared to routine care in TIVA, inhaled and balanced anesthesia patients.^{6,7,8}

Reducing the risk of postoperative delirium

Postoperative delirium is common. Across all surgical procedures requiring anesthesia, 37% to 46% of patients are affected by postoperative delirium.⁹ Risk increases up to 87% depending on the age of patients and the type of surgery.⁹

Monitoring the depth of anesthetic dosing with brain function monitoring may decrease the rate of postoperative delirium in certain patients.^{3,5}



References


1. Chiu CL, Ong G, Majid AA. Impact of bispectral index monitoring on propofol administration in patients undergoing cardiopulmonary bypass. *Anaesthesia Intensive Care*. 2007;35:342-347.
2. Conte V, L'Acqua C, Rotelli S, Stocchetti N. Bispectral index during asleep-awake craniotomies. *J Neurosurg Anesthesiol*. 2013; 25(3):279-284.
3. Gan TJ, Glass PS, Windsor A, et al. Bispectral index monitoring allows faster emergence and improved recovery from propofol, alfentanil, and nitrous oxide anesthesia. BIS Utility Study Group. *Anesthesiology*. 1997;87(4):808-815.
4. White PF, Ma H, Tang J, et al. Does the use of electroencephalographic bispectral index or auditory evoked potential index monitoring facilitate recovery after desflurane anesthesia in the ambulatory setting? *Anesthesiology*. 2004;100(4):811-817.
5. Sebel PS, Bowdle TA, Ghoneim MM, et al. The incidence of awareness during anesthesia: a multicenter United States study. *Anesth Analg*. 2004;99:833-839.
6. Zhang C, Xu L, Ma Y, et al. Bispectral index monitoring prevents awareness during total intravenous anesthesia: a prospective, randomized, double-blinded, multi-center controlled trial. *Chinese Medical Journal*. 2011;124(22):3664-3669.
7. Myles PS, Leslie K, McNeil J, et al. Bispectral index monitoring to prevent awareness during anesthesia: the B-Aware randomised controlled trial. *Lancet*. 2004;363(9423):1757-1763.
8. Ekman A, Lindholm ML, Lennmarken, Sandin R. Reduction in the incidence of awareness using BIS monitoring. *Acta Anaesthesiol Scand*. 2004;48(1):20-26.
9. Whitlock E, Vannucci A, Avidan M. Postoperative Delirium. *Minerva Anesthesiol*. 2011 April; 77(4):448-456.

©2016 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Other brands are trademarks of a Medtronic company. 14-PM-0041c(2)

6135 Gunbarrel Avenue
Boulder, CO 80301

800.635.5267

medtronic.com



Medtronic
Further, Together